Format

Send to

Choose Destination
Br J Cancer. 2009 Feb 10;100(3):431-5. doi: 10.1038/sj.bjc.6604891. Epub 2009 Jan 20.

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

Author information

1
Molecular Oncology Department, The Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. Keiran.Smalley@Moffitt.org

Abstract

The discovery of BRAF mutations in melanoma has not yet translated into clinical success, suggesting that BRAF/MEK inhibitors will need to be combined with other agents. In the current review, we discuss other pathways likely to be important for melanoma progression and suggest possible drug combinations for future clinical testing.

PMID:
19156138
PMCID:
PMC2658537
DOI:
10.1038/sj.bjc.6604891
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center